Evogene (EVGN)
NASDAQ:EVGN
Want to see EVGN full AI Analyst Report?
EVGN Stock Chart & Stats
$1.10
-$0.12(-6.82%)
At close: 4:00 PM EST
$1.10
-$0.12(-6.82%)
Day’s Range― - ―
52-Week Range$0.48 - $1.50
Previous CloseN/A
Volume47.40K
Average Volume (3M)115.16K
Market Cap
$6.04M
Enterprise Value-$1.80M
Total Cash (Recent Filing)$13.09M
Total Debt (Recent Filing)$2.03M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 26, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding12,103,764
10 Day Avg. Volume235,429
30 Day Avg. Volume115,158
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-105.63
Price to Sales (P/S)2.25
P/FCF Ratio-0.64
Enterprise Value/Market Cap-0.30
Enterprise Value/Revenue-0.98
Enterprise Value/Gross Profit2.09
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$2.15Price Target Upside95.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.5
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Cost ManagementCost controls have appropriately been implemented, leading to a lower than expected operating expense and an EBITDA beat despite lower revenues.
Potential GrowthCasterra is believed to be a potential catalyst for the stock via commercial successes, with material value also seen in AgPlenus and Lavie Bio.
Bears Say
Order DelaysDelays in current order delivery and a follow-on order continue to be a material headwind for investors.
Order VisibilityThere is little visibility of a follow-on order at Casterra, which was expected to be a significant commercial catalyst.
Stock DilutionThe diluted share base effectively doubled due to a $5.5M raise, contributing to the decision to lower the price target.
Evogene News
EVGN FAQ
What was Evogene’s price range in the past 12 months?
Evogene lowest stock price was $0.48 and its highest was $1.50 in the past 12 months.
What is Evogene’s market cap?
Evogene’s market cap is $6.04M.
When is Evogene’s upcoming earnings report date?
Evogene’s upcoming earnings report date is Aug 26, 2026 which is in 63 days.
How were Evogene’s earnings last quarter?
Evogene released its earnings results on May 20, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.33.
Is Evogene overvalued?
According to Wall Street analysts Evogene’s price is currently Undervalued.
Does Evogene pay dividends?
Evogene does not currently pay dividends.
What is Evogene’s EPS estimate?
Evogene’s EPS estimate is -0.27.
How many shares outstanding does Evogene have?
Evogene has 12,103,764 shares outstanding.
What happened to Evogene’s price movement after its last earnings report?
Evogene reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went down -3.36%.
Which hedge fund is a major shareholder of Evogene?
Currently, no hedge funds are holding shares in EVGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evogene
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
EVGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented strong technology and pipeline progress — notable AI/Google collaborations, a rapidly growing pharma collaboration slate, and demonstrable iterative success in the Ag fungicide program — which are meaningful strategic achievements. However, these operational and R&D advances are contrasted by material near-term financial weakness: an ~87% revenue decline year-over-year, increased net loss driven largely by financing charges, the termination of a Bayer collaboration for biological reasons, and a modest cash balance that implies limited runway without further funding or cash inflows. Overall, business momentum on the technology and pipeline front is positive, but short-term financial and commercial metrics are weak and present risk.View all EVGN earnings summariesEVGN Stock 12 Month Forecast
Average Price Target
$2.15
▲(95.45% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.03% Mutual Funds
3.85% Other Institutional Investors
95.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---